8.7706.80% ( -0.640 )
Closed: Nov 6, 16:00:00 (EDT)Current ValuationThe current P/E ratio is -10.33, below the reasonable range, cheaper than 89.51% of the time in the past 3 years, and the industry ranks 30/38, the industry Median -0.99.
-10.33xP/E
$8.77Stock price
$-0.85Earnings per share
-10.33xP/E
Stock price$8.77Earnings per share$-0.85
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -5.74x
- Typical range
- -7.76x–-1.46x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
HTFLUSHeartFlow | -38.49x | 74.45% | $4.56B |
SDGRUSSchrodinger | -37.79x | 4.47% | $2.24B |
CERTUSCertara | -28.57x | 2,725.20% | $1.84B |
TDOCUSTeladoc | -10.33x | 26.79% | $1.60B |
MDRXUSVeradigm | -- | -- | $817.38M |
SOPHUSSophia Genetics SA | -7.54x | 19.83% | $611.60M |
EVHUSEvolent Health | -1.02x | 84.75% | $518.02M |
CTEVUSClaritev | -1.36x | 12.62% | $384.88M |
AMWLUSAmerican Well | -3.55x | 61.89% | $202.57M |
DHUSDefinitive Healthcare | -1.06x | 21.33% | $166.57M |
LFMDUSLifeMD | -39.32x | 195.82% | $114.24M |
HCATUSHealth Catalyst | -0.54x | 4.22% | $109.87M |
VSEEUSVSee Health | -5.50x | -- | $54.39M |
RNLXYUSRENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT) | -3.15x | -- | $44.68M |
ONMDUSOneMedNet | -3.62x | -- | $30.47M |
DRIOUSDarioHealth | -3.32x | 60.40% | $23.26M |
AIFFUSFirefly Neuroscience | -1.51x | -- | $14.28M |
ITOCUSiTonic | -1.41x | -- | $12.58M |
BFRGUSBullfrog AI | -1.60x | 41.27% | $9.61M |
SCNXUSScienture | -0.14x | 93.42% | $5.13M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
